Membraneless, self-powered immunosensing of a cardiac biomarker by exploiting a PEC platform based on CaBi2Ta2O9 combined with bismuth oxyiodides.

This work describes the development of a membraneless, self-powered immunosensor exploiting a photoelectrochemical system based on two photoelectrodes for cardiac troponin I (cTn). An electrode based on CaBi2Ta2O9 combined with bismuth oxyiodides (BiOI/Bi4O5I2/Bi5O7I) was modified with the cTnI antibody (anti-cTnI) and applied in a photoelectrochemical cell as a photoanode. To perform the cTnI detection exploiting a self-powered photoelectrochemical setup, the immunosensor (anti-cTnI/BiOI/Bi4O5I2/Bi5O7I/CaBi2Ta2O9/FTO) was coupled to a photoelectrochemical cell containing a photocathode based on CuBi2O4 (CBO/FTO) for zero-biased photoelectrochemical immunosensing of cardiac troponin I (cTnI) biomarker. For comparison purposes, the photoanode was applied for cTnI detection in a three-electrode electrochemical cell. The spectroscopic, structural, and morphological characteristics of the photoelectrochemical (PEC) materials were evaluated using scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), and X-ray diffraction (XRD). Electrochemical impedance spectroscopy (EIS) measurements were performed in the presence and absence of light to investigate the effects of photons on the charge transfer resistance of the photoanode. The influence of the cTnI biomarker on the photoelectrochemical response of the anti-cTnI antibody-modified photoelectrochemical platform (anti-cTnI/BiOI/Bi4O5I2/Bi5O7I/CaBi2Ta2O9/FTO) was evaluated by measuring the photocurrent of the system. The immunosensor presented a linear response ranging from 1 pg mL-1 to 200 ng mL-1 as well as a mean recovery percentage between 95.7% and 108.0% in real human serum samples for the cTnI biomarker.

Immunodiagnostic of leprosy exploiting a photoelectrochemical platform based on a recombinant peptide mimetic of a Mycobacterium leprae antigen.

The first serum diagnosis of leprosy based on the detection of antibodies of patients using a recombinant mimetic peptide (PGL1M3R) as recognition element and exploiting a photoelectrochemical sensor is presented in this work. The photoeletrochemical platform consists of cadmium sulphide and nickel hydroxide electrodeposited on fluorine-doped tin oxide coated glass slide (CdS/Ni(OH)2/FTO). The optical band gap and flat band potential of the photoelectroactive materials were evaluated by UV-Vis spectroscopy and electrochemical impedance spectroscopy. The spatial photoelectrochemical response of the platform was evaluated by Scanning Electrochemical Microscopy and the morphology of the films was investigated by Scanning Electron Microscopy (SEM). The photoelectrochemical response of the CdS/Ni(OH)2/FTO platform was optimized by evaluating the effects of the kind, concentration, and pH of the buffer. Furthermore, the applied potential to the CdS/Ni(OH)2/FTO platform was also investigated. The CdS/Ni(OH)2/FTO photoelectrochemical platform was modified with a synthetic peptide by using glutaraldehyde as cross-linking reagent and chitosan (CS) for the covalent coupling of the peptide to the photoelectrochemical platform (PGL1M3R/CdS/Ni(OH)2/FTO). The photoelectrochemical immunosensor is able to distinguishing between positive and negative leprosy human sera samples diluted from 1:640 up to 1:10240. Furthermore, to test the specificity of the sensor, samples from tuberculosis and leishmaniasis patients were analyzed using the proposed photoelectrochemical immunosensor.

Ascorbic acid reduces the genetic damage caused by miltefosine (hexadecylphosphocholine) in animals infected by Leishmania (Leishamnia) infantum without decreasing its antileishmanial activity.

Leishamaniasis is a neglected disease caused by over 20 Leishmania species, occurring in more than a hundred countries. Miltefosine (hexadecylphosphocholine) is the single oral drug used in treatment for leshmaniases, including cases of infections resistant to pentavalent antimony. Our group has recently demonstrated the ability of miltefosine to cause genomic lesions by DNA oxidation. Acknowledging that antioxidant compounds can potentially modulate Reactive Oxygen Species (ROS), our study verified whether ascorbic acid reduces the genotoxic and mutagenic effects caused by miltefosine, and whether it interferes with drug efficacy. For this purpose, uninfected Swiss mice received simultaneous (single dose treatment) miltefosine and ascorbic acid (gavage and intraperitoneally), besides pre and post treatments (ascorbic acid 24 h before and after drug administration); furthermore, Balb/c mice infected with Leishmania infantum received miltefosine plus ascorbic acid (repeated doses treatment). We conducted comet assays, micronucleus tests, dosages of superoxide dismutase enzyme and parasitic burden by the limiting dilution assay. We observed that ascorbic acid administered intraperitoneally displayed a protective effect over damage caused by miltefosine. However, this effect was not not observed when the same doses were administered via gavage, possibly due to low serum levels of this antioxidant. Ascorbic acid's protective effect reinforces that miltefosine damages DNA by oxidizing its nitrogenous bases, which is reduced by ascorbic acid due to its ability of protecting genetic material from the action of ROS. Therefore, our results show that this drug is efficient in reducing parasitic burden of L. infantum.

The antileishmanial drug miltefosine (Impavido(®)) causes oxidation of DNA bases, apoptosis, and necrosis in mammalian cells.

Miltefosine was developed to treat skin cancer; further studies showed that the drug also has activity against Leishmania. Miltefosine is the first oral agent for treating leishmaniasis. However, its mechanism of action is not completely understood. We have evaluated the induction of DNA damage by miltefosine. Cytotoxicity and genotoxicity (comet assay) tests were performed on human leukocytes exposed to the drug in vitro. Apoptosis and necrosis were also evaluated. In vivo tests were conducted in Swiss male mice (Mus musculus) treated orally with miltefosine. Oxidation of DNA bases in peripheral blood cells was measured using the comet assay followed by digestion with formamidopyrimidine glycosylase (FPG), which removes oxidized guanine bases. The micronucleus test was performed on bone marrow erythrocytes. Miltefosine caused DNA damage, apoptosis, and necrosis in vitro. Mice treated with miltefosine showed an increase in the DNA damage score, which was further increased following FPG digestion. The micronucleus test was also positive.